Chromatographia

, Volume 66, Issue 3–4, pp 291–294 | Cite as

A Stability-Indicating LC Assay and Degradation Behavior of Temozolomide Drug Substances

  • G. Saravanan
  • M. Ravikumar
  • M. J. Jadhav
  • M. V. Suryanarayana
  • N. Someswararao
  • P. V. R. Acharyulu
Limited Short Communication

Abstract

This study deals with a stability indicating HPLC reverse phase method for quantitative determination of temozolomide. A chromatographic separation was achieved on an Inertsil ODS 3V, 250 × 4.6 mm ID, 5 μm column using mobile phase A (buffer 5 mL glacial acetic acid in 1,000 mL of Milli Q water ) and mobile phase B (methanol). Forced degradation studies were performed on bulk sample of temozolomide using acid (0.5 N hydrochloric acid), base (0.5 N sodium hydroxide), oxidation (10% v/v hydrogen peroxide), heat (60 °C) and UV light (254 nm). Degradation of the drug substance was observed in base hydrolysis and oxidation. Degradation product formed under these conditions was found to be Imp-A. When the stress samples were assayed, the mass balance was close to 99.5%. The sample solution was stable up to 48 h at 5 °C and mobile phase was found to be stable up to 48 h at 25 °C. The developed method was validated with respect to linearity, accuracy, precision, robustness and forced degradation studies prove the stability indicating power of the method.

Keywords

Column liquid chromatography Solution and mobile phase stability Forced degradation Validation Temozolomide 

Notes

Acknowledgments

The authors wish to thank the management of Dr. Reddy’s group for supporting this work. Authors wish to acknowledge the process research group for providing the samples for our research. We would also like to thank colleagues in the separation science division of the Analytical Research of High Potent Active Pharmaceutical Ingredients for their co-operation in carrying out this work.

References

  1. 1.
    Ueno T, Ko SH, Grubbs E, Pruitt SK, Friedman HS, Tyler DS (2004) Am J Surg 188:532–537CrossRefGoogle Scholar
  2. 2.
    Basso U, Ermani M, Reni M, Vastola F, Tosoni A, Pasetto LM, Coria B, Cacciacarne M, Sala F, Brandes AA (2003) Eur J Cancer 1:S95Google Scholar
  3. 3.
    Intensive and Critical Care Nursing (2000) 16:59–60Google Scholar
  4. 4.
    Siker ML, Chakravarti A, Mehta MP (2006) Crit Rev Oncol/Hematol 60:99–111CrossRefGoogle Scholar
  5. 5.
    Giorgio CG, Giuffrida D, Pappalardo A, Russo A, Santini D, Salice P, Blanco G, Castorina S, Failla G, Bordonaro R (2005) Lung Cancer 50:247–254CrossRefGoogle Scholar
  6. 6.
    International conference on harmonization October (1994), Text on Validation of Analytical Procedures Q2AGoogle Scholar
  7. 7.
    Kim H, Likhari P, Parker D, Statkevich P, Marco A, Lin CC, Nomeir AA (2001) J Pharm Biomed Anal 24:461–468CrossRefGoogle Scholar
  8. 8.
    Chowdhury SK, Laudicina D, Blumenkrantz N, Wirth M, Alton KB (1999) J Pharm Biomed Anal 19:659–668CrossRefGoogle Scholar
  9. 9.
    Kim HK, Lin CC, Parker D, Veals J, Lim J, Likhari P, Statkevich P, Marco A, Nomeir AA (1997) J Chromatogr B: Biomed Sci Appl 703:225–233CrossRefGoogle Scholar
  10. 10.
    International conference on harmonization November (1996), Validation of analytical procedures methodology Q2BGoogle Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlag/GWV Fachverlage GmbH 2007

Authors and Affiliations

  • G. Saravanan
    • 1
  • M. Ravikumar
    • 1
  • M. J. Jadhav
    • 1
  • M. V. Suryanarayana
    • 1
  • N. Someswararao
    • 2
  • P. V. R. Acharyulu
    • 3
  1. 1.Analytical Research, High Potent Active Pharmaceutical Ingredients OperationsDr. Reddy’s LaboratoriesHyderabadIndia
  2. 2.Department of Inorganic and Analytical ChemistryAndhra UniversityVisakhapattanamIndia
  3. 3.Process Research, High Potent Active Pharmaceutical Ingredients OperationsDr. Reddy’s LaboratoriesHyderabadIndia

Personalised recommendations